Added to YB: 2026-05-01
Pitch date: 2026-04-29
TBPH [neutral]
Theravance Biopharma, Inc.
+0.97%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States.
Market Cap
$863.0M
Pitch Price
$16.58
Price Target
N/A
Dividend
N/A
EV/EBITDA
-293.14
P/E
8.14
EV/Sales
5.39
Sector
Pharmaceuticals
Category
special_situation
Show full summary:
Watchlist Radar - Theravance Biopharma, Inc.
TBPH (watchlist): Lead phase 3 program failed, pivoting to strategic review w/ 50% G&A cut. Remainco has ~$400M cash, $100M 2026 milestone (low hurdle), ~$2.6B Irish tax assets, $60-70M/yr FCF from YUPELRI royalty (Viatris, patent to 2039). $463M EV vs strong asset base + FCF stream = potential value unlock.
Read full article (1 min)